论文部分内容阅读
目的评价尿激酶(UK)溶栓治疗脑梗死的临床疗效及安全性。方法采用国产尿激酶100～150万U静脉滴注,对66例发病在6小时以内的急性脑梗死患者进行溶栓治疗,比较治疗前后神经功能缺损评分(NF-DI)。另设60例普通病例作对照组。结果溶栓后2小时NFDI为21.39±2.81,较溶栓治疗前25.96±3.29明显减少(P<0.001),治疗后21天溶栓组NFDI为19.01±3.35,明显低于对照组,治疗后21天溶栓治疗组的治愈率、显效率、总有效率分别为30.3%、66.7%、83.3%,显著高于对照组。两组比较有显著差异。结论在严格掌握溶栓治疗适应症的基础上应用尿激酶静脉溶栓治疗急性脑梗死疗效好并发症小。
Objective To evaluate the clinical efficacy and safety of urokinase (UK) thrombolytic therapy for cerebral infarction. Methods Thrombolytic therapy was performed in 66 patients with acute cerebral infarction within 6 hours after intravenous infusion of 0.1-1.5 million U.U.U., and the neurological deficit score (NF-DI) was compared between the two groups. Another 60 cases of common cases for the control group. Results NFDI was 21.39 ± 2.81 two hours after thrombolysis, which was significantly lower than that of 25.96 ± 3.29 before thrombolytic therapy (P <0.001). After 21 days of treatment, the NFDI in thrombolysis group was 19.01 ± 3.35, which was significantly lower than that in control group The cure rate, effective rate and total effective rate of the thrombolytic therapy group were 30.3%, 66.7% and 83.3% respectively, significantly higher than that of the control group. There were significant differences between the two groups. Conclusion The strict control of thrombolytic therapy based on the application of intravenous thrombolytic therapy of urokinase in acute cerebral infarction with good efficacy and small complications.